Cell biology

Allen Institute joins the Weill Neurohub

Retrieved on: 
Wednesday, March 6, 2024
Engineering, UCSF, Head, Nervous system, Helen Wills Neuroscience Institute, AI, Neurology, Stroke, DSM-IV codes, Faculty, University, Cell biology, UC, Chronic pain, Organization, Knowledge, Disease, Genomics, Science, Biology, Brain, Research, Allen Institute, University of California, Berkeley, Partnership, Pharmaceutical industry

SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases. 

Key Points: 
  • SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub , a collaborative research network advancing treatments for neurological diseases.
  • Founded in 2003 by philanthropist Paul G. Allen, the Allen Institute focuses on big questions in biology through a team-based, open science approach, and currently has moonshot projects in neuroscience, cell biology, and immunology institutes.
  • "The expansion of the Weill Neurohub and our formal partnership with the Allen Institute represents a powerful joining of forces in neuroscience," said Stephen Hauser, M.D., the Robert A. Fishman Distinguished Professor of Neurology at UCSF and director of the UCSF Weill Institute for Neurosciences.
  • These collaborative sessions are intended to spark new joint projects and residencies, focusing on the scientific pillars of the Weill Neurohub.

Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Sigma-Aldrich, Epigenomics, Cornell University, MAI, Bruker, Abraxis BioScience, Principal, Biotechnology, Research, General partnership, Viridos (company), NGS, St. Louis, Biophysics, Protein engineering, Doctor of Philosophy, Gen-Probe, Synthetic biology, Gene editing, Cell biology, Dicarboxylic acid, Gene, Oligonucleotide, Thermo Fisher Scientific, Genomics, Horizon Discovery, CTAB, DNA, Fine chemical

"With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.

Key Points: 
  • "With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products," said Larry Stambaugh, Board Chair of Molecular Assemblies.
  • "Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides," said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director.
  • He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.
  • His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field.

In-Vitro Diagnostics Business Updates Service - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Medical Devices, Health, Agilent Technologies, Cell biology, Prenatal development, Molecular diagnostics, Business, Pharmaceutical industry

Figure: Agilent Sales, by Business (Agilent Crosslab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), Fy 2022 and Fy 2023

Key Points: 
  • Figure: Agilent Sales, by Business (Agilent Crosslab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), Fy 2022 and Fy 2023
    Figure: Agilent Sales, by Business (Agilent Crosslab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), Fy 2023 Quarterly Performance
    Figure: Agilent Fy 2023 Regional Sales Breakdown Distribution, by Region (Americas, Asia-Pacific, Europe) (%)
    Table: Hologic Diagnostic Sales Performance, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), Fy 2023 ($ Millions)
    Figure: Hologic Revenue, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), Fy 2022 and Fy 2023 ($ Millions)

Nabla Appoints Clinical Leader Dr. Ed Lee as its Chief Medical Officer

Retrieved on: 
Thursday, February 8, 2024
TPMG, Policy, Cell biology, RCM, Associate, Public, Kaiser Permanente, American Medical Informatics Association, University, Informatics, Physician, Internal medicine, MPH, Health informatics, AMIA, Documentation, Patient, Nabla, First officer (aviation), Tufts University, College of Medicine, Nursing

Bringing 20 years of clinical and operational leadership experience, Dr. Lee will help drive Nabla's product vision and development

Key Points: 
  • Bringing 20 years of clinical and operational leadership experience, Dr. Lee will help drive Nabla's product vision and development
    BOSTON, Feb. 8, 2024 /PRNewswire/ -- Nabla , the leading ambient AI assistant for practitioners, today announced the appointment of Ed Lee, MD, MPH , as Chief Medical Officer.
  • He brings his expansive clinical expertise, executive experience, and Nabla Copilot implementation insights to the company to help refine and enhance the product and deployment strategy.
  • As Chief Medical Officer, Dr. Lee will be instrumental in shaping Copilot's clinical strategy and product roadmap, including RCM optimization, and he will provide feature refinement and enhancement recommendations to solidify Nabla as a leader in healthcare ambient AI.
  • He will also represent Nabla at the American Medical Informatics Association (AMIA), offering insights on the field of clinical informatics and contributing to AMIA policy responses.

Celebrating Excellence in Anatomy: AAA Awards Distinguished Members

Retrieved on: 
Thursday, February 8, 2024
Pennsylvania State University, Harvard Medical School, California University, Cell biology, The Anatomical Record, Developmental Dynamics, Stanford University, North Carolina State University, Boston Children's Hospital, Public health, School, Cell, Conference, Associate, Medical education, Mentorship, McGill University, Human body, Hospital, Biomedical sciences, Pediatrics, Anatomical Sciences Education, Forensic anthropology, Anschutz Medical Campus, Dental school, Student, University, AAA, Genetics, Outline of health sciences, Research, Physiology, City University, Chemical engineering, Arkansas College, Division, Orthopedic surgery, UCSF, Dentistry

ROCKVILLE, Md., Feb. 8, 2024 /PRNewswire/ -- The American Association for Anatomy (AAA) is honored to announce its 2024 awards recipients. Eighteen of the association's 2,455 members have been selected because they advanced AAA's values: community, respect, inclusion, integrity, and discovery. 

Key Points: 
  • ROCKVILLE, Md., Feb. 8, 2024 /PRNewswire/ -- The American Association for Anatomy (AAA) is honored to announce its 2024 awards recipients.
  • Eighteen of the association's 2,455 members have been selected because they advanced AAA's values: community, respect, inclusion, integrity, and discovery.
  • The AAA awards program provides over $650,000 in awards, research grants, and scholarships annually.
  • "Being recognized by my AAA idols, mentors, and peers is a cherished honor, reaffirming my commitment to fostering curiosity, deep understanding, and innovation in anatomy education."

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Retrieved on: 
Monday, February 5, 2024
Research, General Health, Pharmaceutical, Data Management, Technology, Semiconductor, Science, Biotechnology, Stem Cells, Other Technology, Other Science, Health, Epithelium, Laboratory automation, Cell biology, Electronics, Cell, B cell, Harvard University, Electrophysiology, USD, Exhibition, Data science, Medium (website), Drug discovery, Computer, Pixel, Metabolism, SLAS, Toxicology, Data collection, Television

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.

Key Points: 
  • Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.
  • Pixel delivers simultaneous multi-modal, high-resolution readouts in 96- or 384-well plates, enabling cell monitoring and data collection at unprecedented scale.
  • It’s widely applicable for in vitro cell biology applications including drug discovery, from target validation to toxicology screening.”
    CytoTronics’ early-access program for Pixel Primo empowers cell biologists to unlock applications that were previously inaccessible.
  • The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Opentrons® Unveils New Protocol Library and Generative AI Tools to Accelerate Lab Automation and Scale Scientific Research

Retrieved on: 
Thursday, February 1, 2024
Data Management, Technology, Health, Robotics, Other Science, Medical Devices, Research, Software, Artificial Intelligence, Genetics, Science, Cell biology, Ecosystem, Database, Exhibition, Disease, Genomics, Proteomics, Convention center, SLAS, Carnegie Mellon University, MIT, Genome, Conference, Synthetic biology, Consumer electronics

Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of its new protocol library, offering plug-and-play protocols for all Opentrons robots, including the Opentrons Flex™.

Key Points: 
  • Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of its new protocol library, offering plug-and-play protocols for all Opentrons robots, including the Opentrons Flex™.
  • Opentrons is building a first-of-its-kind ecosystem for simplifying and scaling lab automation, which comprises the protocol library along with generative AI tools for protocol development, coupled with stringent wet- and dry-lab verification processes.
  • The aim is to create the largest open-access set of robust liquid-handling automation protocols to streamline research across genomics, proteomics, cell biology, and synthetic biology.
  • “With hundreds of protocols already developed by our community of users and internal scientific team, the easily accessible protocol library and our latest innovation in generative-AI protocol development tools both mark a major milestone for scientists.

Deepcell Unveils Innovative AI-Powered Single Cell Morphology Data at Leading Scientific Meetings

Retrieved on: 
Thursday, February 1, 2024
Science, Software, Biotechnology, Research, Health, Artificial Intelligence, Data Management, Technology, SLAS, NVIDIA, Society, Laboratory automation, RNA-Seq, Intelligence, Cell biology, Conference

In addition, the company announced that its REM-I Platform is a finalist for the New Product Award at SLAS.

Key Points: 
  • In addition, the company announced that its REM-I Platform is a finalist for the New Product Award at SLAS.
  • “We look forward to sharing the tremendous progress we’ve made as a company with the scientific community at these meetings.
  • A year ago, we were presenting our first public datasets at AGBT and attending SLAS for the first time.
  • This year, we have the REM-I Platform in field testing, are presenting substantially more data, and look forward to the full commercialization of our instrument later this year,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell.

Pixelgen Technologies Signs Distribution Agreement in Japan

Retrieved on: 
Thursday, February 1, 2024
Medicine, Cell biology, MPX, Research, Immunotherapy, DNA, 3D, Proteome, COVID, University, Protein, Disease, Computational biology, NGS, Hematology, Health, Vaccine

STOCKHOLM and TOKYO, Feb. 1, 2024 /PRNewswire/ -- Pixelgen Technologies® announced today that it has signed a non-exclusive agreement with BioStream Co. Ltd of Japan to distribute its groundbreaking spatial proteomics tools for single cells. The agreement comes upon growing customer demand for Pixelgen's first product for spatial proteomics of single cells by next-generation sequencing, which launched last year.

Key Points: 
  • STOCKHOLM and TOKYO, Feb. 1, 2024 /PRNewswire/ -- Pixelgen Technologies ® announced today that it has signed a non-exclusive agreement with BioStream Co. Ltd of Japan to distribute its groundbreaking spatial proteomics tools for single cells.
  • The agreement comes upon growing customer demand for Pixelgen's first product for spatial proteomics of single cells by next-generation sequencing, which launched last year.
  • "We are extremely pleased to partner with BioStream, a world-class and well-established distributor in Japan," said Pixelgen Chief Commercial Officer Annika Branting.
  • "With growing demand for our first product, this distribution agreement marks an important first step toward establishing a strong global distribution network.

Gene-Based Therapy May Slow Development of Life-Threatening Heart Condition

Retrieved on: 
Tuesday, January 30, 2024
DSM-IV codes, NYU Langone Health, Survival, Circulation, Cell, PKP2, Research, Arrhythmia, Human, Heart, Cell biology, Ischemia, Patient, Mouse, Safety, Personalized medicine, NYU, MBA, Blood, Chantal, Disease, Risk, ARVC, Doctor of Philosophy, Cardiomyopathy, Cerrone

The heart can also beat irregularly without any warning and sometimes stops working.

Key Points: 
  • The heart can also beat irregularly without any warning and sometimes stops working.
  • While current therapies can help restore the heart's normal rhythm and control symptoms, they fail to provide a cure.
  • "Our findings offer experimental evidence that gene therapy targeting plakophilin-2 can interrupt the progression of a deadly heart condition," says study co-lead author Chantal van Opbergen, PhD, a postdoctoral research fellow at NYU Langone Health.
  • According to the study authors, the most advanced stages of ARVC are marked by irreversible heart damage, sometimes requiring a heart transplant.